- Email: [email protected]
- Telephone: +49 892 102 320
- Fax: +49 892 194 940 8
- Website: http://www.wallinger.com
Mathias Ricker is one of the founding partners of law firm WALLINGER RICKER SCHLOTTER TOSTMANN. He leads the chemistry/pharmaceutical IP practice group, together with a second partner, Holger Tostmann.
Before co-founding WALLINGER RICKER SCHLOTTER TOSTMANN, Dr Ricker was a partner with Jones Day, also acting as European IP coordinator. He holds a PhD in chemistry and has been admitted as a German patent attorney since 1994 and as a European patent attorney since 1995.
Dr Ricker has been active in the IP field since 1991. His recent activities have focused on the areas of chemistry, pharmaceuticals and medical devices. He is active in counselling domestic and foreign clients in all areas of patent matters, providing representations in opposition and nullity proceedings before the European Patent Office (EPO) and the Federal Patent Court, as well as in infringement proceedings – in many instances together with WALLINGER RICKER SCHLOTTER TOSTMANN’s attorneys at law and patent attorneys with a mechanical or physical technical background.
Among other things, he has represented AstraZeneca in various cases relating to omeprazole; Eppendorf AG and Promega with regard to different aspects relating to polymerase chain reaction technology, including before the Federal Court of Justice; and Merz Pharma GmbH in the area of botulinum toxin in opposition/appeal and infringement proceedings, mainly together with WALLINGER RICKER SCHLOTTER TOSTMANN’s attorneys at law. He also represents a significant number of clients – including Abbott Labs, Archroma IP GmbH (the former paper and textile business of Clariant), Eastman Chemicals, Fresenius Medical Care and Merck KGaA – in opposition proceedings and patent prosecution before the EPO.
Located in Munich, WALLINGER RICKER SCHLOTTER TOSTMANN started with five attorneys in 2007 and has grown to include more than 20 patent attorneys and attorneys at law.